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INTRODUCTION
Albinism is an inherited condition affecting approximately 
one in 17,000 persons and is characterized by absent or 
reduced pigmentation in the skin, hair, and eyes (oculocu-
taneous albinism [OCA]), or only the eyes (ocular albinism) 
(C. J. Witkop, 1979). There are various associated manifesta-
tions, including systemic pathologies in syndromic albinism. 
Hypopigmentation may be subtle and missed in neonates 
and become apparent only with age and sun exposure, and 
ocular abnormalities and systemic complications may not 
develop for years, leading to delayed diagnoses and treat-
ment (Torres-Serrant, Ramirez, Cadilla, Ramos-Valencia, & 
Santiago-Borrero, 2010). Therefore, it is imperative to con-
firm a diagnosis of albinism and to be aware of the systemic 
symptoms of associated syndromes. Although most persons 
with albinism have a presentation limited to OCA, in the face 
of additional symptoms, one must consider syndromes such 
as Hermansky-Pudlak syndrome (HPS), Chediak-Higashi syn-
drome (CHS), and Griscelli syndrome (GS). 
PATHOGENESIS OF PIGMENTATION
Melanocytes are derived from neural crest precursors known 
as melanoblasts, which are guided by signaling pathways 
toward destinations including the basal epithelium of the 
epidermis, the hair bulbs of the skin, and the uveal tract of 
the eye (Dessinioti, Stratigos, Rigopoulos, & Katsambas, 
2009). Once in target sites, melanoblasts differentiate into 
functional melanocytes by synthesizing melanin within lys-
osome-like organelles called melanosomes, within which 
tyrosine is converted to melanin. Melanosomes are then 
transferred via melanocytic dendrites to surrounding kerati-
nocytes (Dessinioti et al., 2009).
Melanin is derived from tyrosine and its synthesis is pri-
marily regulated by tyrosinase, P gene, tyrosinase-related 
protein 1 (TYRP1), and membrane-associated transporter 
protein (MATP), which are each mutated in the OCA sub-
types (Figure 1). Tyrosinase catalyzes the hydroxylation of 
tyrosine to dopaquinone in the bottleneck step of melanin 
synthesis. Diversion to two pathways then occurs, with one 
synthesizing the eumelanin that composes brown and black 
pigments, and the other synthesizing pheomelanin, which is 
responsible for blonde and reddish pigments (Levin & Stroh, 
2011). Pigmentation is therefore affected by several factors: 
host cell presence, melanosome formation, and the quan-
tity of melanin within melanosomes. Of note: while OCA is 
associated with defects in melanin production, syndromic 
albinism is attributed to defective formation and transport 
of melanosomes (Scheinfeld, 2003). 
OCULOCUTANEOUS ALBINISM
OCA is a group of autosomal recessive (AR) disorders 
caused by absent or deficient melanin biosynthesis, mani-
festing as generalized hypopigmentation of the hair, skin, 
and eyes and ocular abnormalities. It is attributed to defects 
in four genes (OCA1–4), with much of the phenotypic varia-
tion attributed to compound heterozygosity (Gronskov, Ek, 
& Brondum-Nielsen, 2007). 
The degree of skin and hair pigmentation varies according 
to the type of OCA. Iris hypopigmentation is associated 
with reduced visual acuity, nystagmus, photophobia, foveal 
hypoplasia, strabismus, refractive error, color-vision impair-
ment, and amblyopia. These defects may be related to 
abnormal misrouting of the optic nerves (Creel, Summers, 
& King, 1990). Visual evoked potentials reveal characteristic 
patterns representing abnormal decussation and can con-
firm OCA (Moss, 2000). Nystagmus, which is typically the 
most clinically apparent ocular abnormality, may not appear 
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Although albinism may be considered a simple diagnosis, 
its clinical manifestations, which include hypopigmenta-
tion of the skin, hair, and eyes and ocular abnormalities 
such as nystagmus and reduced visual acuity, are often 
subtle and initially missed. In oculocutaneous albinism, 
there is wide phenotypic variability, which correlates with 
specific mutations in genes with roles in melanin biosyn-
thesis. Additionally, syndromic forms of albinism such as 
Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, 
and Griscelli syndrome are associated with serious com-
plications such as bleeding abnormalities, lysosomal stor-
age defects, immunodeficient states, and progressive 
neurologic defects, which all can result in mortality. It is 
critical to confirm a suspicion of albinism and perform an 
appropriate workup involving molecular testing in order to 
establish a diagnosis. Given the various subtypes of ocu-
locutaneous albinism and the life-threatening complica-
tions in syndromic forms of albinism, a diagnosis permits 
proper genetic counseling and timely implementation of 
necessary screenings and treatments. Recommendations 
regarding sun exposure and treatment of ocular abnor-
malities are imperative in oculocutaneous albinism, and 
preventive therapies should be implemented in syndromic 
forms. With knowledge of the differential in conjunction 
with the execution of simple diagnostic tests, many of 
these complications can be predicted and consequently 
ameliorated or prevented.
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until the patient is 2 to 3 months old. Parents may initially 
think that the infant is unable to fixate on targets, as the nys-
tagmus manifests in a large-amplitude and low-frequency 
pattern (Levin & Stroh, 2011; Moss, 2000). With age, the 
nystagmus becomes pendular, followed by development of 
the typical jerk nystagmus (Levin & Stroh, 2011). 
Type 1 OCA (OCA1) is itself divided into four subtypes, all 
bearing mutations in the tyrosinase gene (TYR), which is 
mapped to chromosome 11q14-2. Phenotypic manifesta-
tions of each subtype are directly related to the type of TYR 
mutation.
Type 1A OCA is the most clinically severe, as tyrosinase 
activity is absent secondary to a null mutation in each copy 
of TYR (Giebel, Musarella, & Spritz, 1991). Individuals with 
this mutation are born with white skin and hair and light-
blue to pink irises; they later manifest nystagmus, poor 
visual acuity, and prominent photophobia. Their skin cannot 
tan and can develop only amelanotic nevi.
Type 1B OCA is caused by a point mutation in TYR that 
changes the conformation of tyrosinase or causes new 
splicing sites (Matsunaga et al., 1999). Decreased tyrosi-
nase activity permits some melanin accumulation over time. 
Although at birth the phenotype may be indistinguishable 
from that of type 1A, pigment may rapidly accumulate. Hair 
may grow with a white-tipped pattern and appear blonde or 
light brown, due to preferential shunting to the pheomela-
nin pathway, and iris color may change from blue to green 
or brown (Giebel et al., 1991; Gronskov et al., 2007). As 
in type 1A, vision is moderately to severely reduced, with 
prominent nystagmus developing soon after birth.
Type 1MP OCA, the “minimal pigment” form of OCA1, has 
decreased tyrosinase activity, permitting some pigment, 
with blonde hair color and pigmented nevi developing. 
Type 1 TS OCA is the “temperature-sensitive” form result-
ing from a TYR missense mutation that produces tyrosinase 
with activity that varies according to temperature (Giebel et 
al., 1991). While its initial presentation may also be indistin-
guishable from that of type 1A, during puberty tyrosinase 
function becomes normal in the cooler areas of the body, 
producing dark hair on the arms, legs, and chest; white 
hair remains in the warmer areas, including the axilla, pubic 
region, and scalp (Levin & Stroh, 2011). 
The molecular genetic defect in Type 2 OCA (OCA2) is in 
the P gene, now known as OCA2, mapped to 15q11.2–11.3 
(Ramsay et al., 1992). It encodes a melanosomal mem-
brane protein that regulates the influx of proteins such as 
TYR and TYRP1 (Levin & Stroh, 2011). Manifesting with 
some pigment production, skin and hair color range from 
white to fair and yellow to black, and eyes are typically 
Figure 1 | Melanosome formation and melanin biosynthesis in the melanocyte and melanosome, respectively. (A) Melanosome 
biogenesis within the melanocyte and sorting of melanosome proteins TYR and TYRP1 from the endoplasmic reticulum and golgi to 
the developing melanosome via OCA2 and MATP proteins. Minor TYR or TYRP1 mutations lead to proteasome degradation, causing 
disease. Mutations in TYR, OCA2, TYRP1, and MATP cause OCA1, OCA2, OCA3, and OCA4, respectively. (B) Melanin biosynthesis may 
be disrupted by TYR or TYRP1 mutations, causing OCA1 and OCA3, respectively. Adapted from Grosnkov, Ek, & Brondum-Nielsen, 2007. 
TYR: tyrosinase, TYRP1: tyrosinase-related protein 1.
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light blue with improved ocular function compared to the 
1A phenotype. Newborns usually have pigmented hair 
and irises, with typical nevi and ephileds (Gronskov et al., 
2007). Clinically, OCA2 is most comparable to types 1B and 
1MP and it is the most prevalent form worldwide, affect-
ing about one in 10,000 African Americans (Oetting & King, 
1999). Approximately one in 100 patients with Prader-Willi 
or Angelman syndromes also manifest OCA2, as OCA2 is 
located in the region of chromosome 15 between the genes 
responsible for these syndromes (Lee et al., 1994). 
Type 3 OCA (OCA3) is caused by mutations in TYRP1, which 
encodes an enzyme that catalyzes eumelanin formation and 
stabilizes TYR (Toyofuku et al., 2001). As this type presents 
with a minimally hypopigmented phenotype, it is almost 
exclusively described in South African blacks, although it 
has recently been described in other populations (Tomita 
& Suzuki, 2004; K. H. Zhang et al., 2011). Mutations in 
TYRP1 are responsible for brown or rufous albinism; brown 
albinism presents with light-brown skin pigment, beige to 
light-brown hair, and blue-green to brown irises, while the 
rufous phenotype is characterized by a red-bronze skin with 
nevi, ginger-red hair, and blue or brown irises (Kromberg et 
al., 1990). In one Caucasian patient with TYRP1 mutation, 
hair was yellow-gold with orange highlights. Otherwise, the 
phenotype was indistinguishable from types 1B and OCA2 
(Rooryck, Roudaut, Robine, Musebeck, & Arveiler, 2006).
Type 4 OCA is caused by mutations in MATP, which has sug-
gested roles in protein transport and melanosome function. 
The clinical phenotype is similar to type 1A OCA but is most 
common in Japan (Tomita & Suzuki, 2004). 
There are increasing numbers of OCA subtypes due to 
digenic inheritance. For example, a mutation in the microph-
thalmia-associated transcription factor (MITF) gene com-
bined with a TYR mutation produces ocular albinism with 
deafness, which may be attributed to melanin’s role within 
the stria vasculosa of the ear (Chiang, Spector, & McGregor, 
2009). Due to clinical overlap among the various types of 
OCA and increasing subtypes, molecular diagnosis permits 
proper counseling, implementation of appropriate precau-
tions and interventions, and differentiation from subtypes 
with defined morbidities and mortality. 
SYNDROMIC OCULOCUTANEOUS ALBINISM
Hermansky-Pudlak Syndrome
HPS is a rare AR disease, affecting one in 500,000 to 
1,000,000 persons, but it is quite common in Switzerland 
and Puerto Rico, affecting one in 1,800 northwestern Puerto 
Ricans (C. J. Witkop et al., 1990). This syndrome is attributed 
to at least nine distinct genetic defects causing subtypes 
HPS1–9 and is characterized by OCA, bleeding abnormali-
ties, and lysosomal ceroid storage defects in some subtypes 
(Krisp, Hoffman, Happle, Konig, & Freyschmidt-Paul, 2001). 
HPS gene products were identified as subunits of at least 
three multiprotein complexes named biogenesis of lyso-
some-related organelle complex (BLOC) -1, -2, and -3, with 
roles in intracellular protein trafficking and newly defined 
interactions with the actin cytoskeleton (Dell’Angelica, 
2004; Ryder et al., 2013). The symptoms are attributed to 
abnormalities in the function and formation of intracellular 
vesicles, such as melanosomes in melanocytes, dense bod-
ies in platelets, and lytic granules in T cells, neutrophils, 
and lung type II epithelial cells (Dessinioti et al., 2009; Wei, 
2006). Albinism results from protein mistrafficking that dis-
ables melanosome production, forming macromelanosomes 
that can be observed on skin biopsy (Levin & Stroh, 2011). 
The platelet dysfunction is attributed to deficiency of dense 
bodies, which normally trigger the secondary aggregation 
response. This leads to a prolonged bleeding time with nor-
mal platelet counts and normal coagulation factor activity 
(Torres-Serrant et al., 2010). The lysosomal storage defect 
is demonstrated by a yellow, autofluorescent, amorphous 
lipid-protein complex, called ceroid lipofuscin, in urinary 
sediment and parenchymal cells; it predisposes patients to 
the development of granulomatous colitis, renal failure, car-
diomyopathy, and pulmonary fibrosis. 
The HPS1 gene, located on chromosome 10q23.1–q23.3, 
encodes a transmembrane protein that regulates protein 
traffic targeted to melanosomes. It is the most frequently 
presenting HPS mutation and is phenotypically very similar 
to HPS4 (Wei, 2006). HPS1 and HPS4 are the most severely 
affected of the subtypes, with prominent OCA, prolonged 
bleeding, complications from granulomatous colitis, and 
early death from pulmonary fibrosis. The HPS4 gene is 
mapped on chromosome 22q11.2–q12.2, and intracellular 
HPS1 and HPS4 proteins associate together in BLOC-3 (Wei, 
2006). 
HPS2 can be clinically distinguished, as it causes immuno-
deficiency and manifests with congenital neutropenia and 
recurrent respiratory illness (Jung et al., 2006). It is attrib-
uted to mutations in the AP3B1 gene, which encodes the 
Beta3A subunit of the heterotetrameric adaptor protein 
complex known as adaptor protein-3 (AP-3), which acts 
in mediating cargo-protein selection in transport vesicles 
and in sorting proteins to lysosomes (Dell’Angelica, 2004; 
Wei, 2006). The immunodeficiency is caused by a deficient 
AP3-dependent antigen presentation pathway and loss of 
microtubule-mediated movement of enlarged lytic granules 
in cytotoxic T-lymphocytes, among other innate immunity 
defects (Fontana et al., 2006; Sugita et al., 2002). 
The HPS3 gene is mapped to chromosome 3q24 and con-
tains sorting signals for targeting to vesicles (Anikster et al., 
2001). It is commonly associated with central Puerto Rican 
or Ashkenazi Jewish ancestry and is clinically similar to HPS5 
and HPS6, presenting with very mild skin hypopigmenta-
tion, ocular albinism, visual acuity of approximately 20/100 
or better, and mild bruising, without colitis or pulmonary 
fibrosis. The defective proteins in HPS3, HPS5, and HPS 6 
interact with one another in BLOC-2 and regulate organelle 
biosynthesis (Huizing et al., 2009; Q. Zhang et al., 2003). 
HPS5, however, is uniquely reported to have elevated cho-
lesterol levels (Dessinioti et al., 2009; Wei, 2006).
There is a single report of a patient with HPS7, with a 
mutation in the dysbindin gene, DTNBP1 on chromosome 
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6p22.3, which encodes a component of BLOC-1; the patient 
presented with OCA, bleeding tendency, and decreased 
lung compliance (Li et al., 2003). HPS8 and HPS9 are also 
caused by mutations in BLOC-1. HPS8 is attributed to a 
mutated BLOC-3 gene (BLOC1S3) and is detected in a large 
consanguineous Pakistani family with incomplete OCA and 
platelet dysfunction. The proband was born with silvery hair 
that later darkened, hazel eyes, and pale skin that reddened 
in the sun (Morgan et al., 2006). HPS9 is associated with a 
mutation in the pallidin gene (PLDN), and clinically mani-
fested with albinism and immunodeficiency in one patient 
(Cullinane et al., 2011). 
A delay in diagnosis of HPS can be attributed to clinical vari-
ability (Torres-Serrant et al., 2010). Although hypopigmenta-
tion can be subtle at birth, nearly all patients with HPS have 
nystagmus (Gradstein et al., 2005). Early on, nystagmus is 
very fast and later slows as additional ocular abnormali-
ties, such as wandering eye movements, become promi-
nent. Typically, bleeding abnormalities initially present with 
bruising upon ambulation, but they may occur earlier with 
circumcision or trauma. One report detailed an infant who 
had a complicated delivery necessitating forceps and pre-
sented at 7 weeks old with seizures and associated subdural 
hematomas and retinal hemorrhages. The infant was found 
to have abnormal platelet function and was later diagnosed 
with HPS (Russell-Eggitt, Thompson, Khair, Liesner, & Hann, 
2000). Epistaxis usually occurs in childhood, and prolonged 
bleeding with menses or after tooth extraction or any surgi-
cal procedure is typical. As ceroid accumulation increases 
with age, granulomatous colitis resembling Crohn’s disease 
presents on average at 15 years old and occurs in 15 per-
cent of cases, while pulmonary fibrosis typically does not 
become symptomatic until the patient’s thirties and is usu-
ally fatal (Avila et al., 2002). 
The diagnosis of HPS is established both clinically and via 
demonstration of absent dense bodies on whole-mount 
electron microscopy of platelets. Bleeding-time or platelet-
aggregation abnormalities and tissue biopsy showing ceroid 
deposition may assist in diagnosis (Levin & Stroh, 2011). 
Sequence analyses for HPS1-8 mutations are available on a 
clinical basis and for HPS9 on a research basis only. 
Given the bleeding risks in HPS, the platelet function of indi-
viduals with suspected albinism should be evaluated prior 
to surgical procedures. Although the bleeding diathesis is 
usually mild, death from hemorrhage has been reported 
(Theuring & Fiedler, 1973). In addition, bleeding in HPS 
has been controlled by administering desmopressin prior 
to surgery (Zatik, Poka, Borsos, & Pfliegler, 2002) and by 
making platelet concentrates available during surgery. It is 
important to be aware that aspirin and indomethacin are 
contraindicated in patients with HPS, as they exacerbate the 
platelet abnormality (Witkop, White, Gerritsen, Townsend, 
& King, 1973). 
Chediak-Higashi Syndrome
CHS is a rare AR disease that is characterized by partial 
OCA with characteristic silvery hair and bleeding tendency, 
peripheral neuropathy, and immune deficiency (Dessinioti 
et al., 2009). This syndrome arises due to mutations in the 
CHS1/lysosomal trafficking regulator (LYST) gene, located 
on chromosome 1q42–43, which has roles in membrane 
identification and intravesicular sorting. Various vesicles are 
affected, and diagnosis is via visualization of pathognomonic 
giant peroxidase-positive cytoplasmic granules in neutro-
phils on a peripheral blood smear (Tomita & Suzuki, 2004). 
Abnormal granules can also be found in melanocytes, fibro-
blasts, endothelial cells, neurons, and Schwann cells, and 
Table 1 | Subtypes of oculocutaneous albinism and syndromic albinism with associated genes and symptoms.
Disease Gene Symptoms
OCA 
         OCA1
         OCA2
         OCA3
         OCA4
TYR
P gene/OCA2
TYRP1
MATP
OCA
HPS
         HPS1-6
         HPS7
         HPS8
         HPS9
HPS1-6
DTNBP1
BLOC1S3
PLDN
OCA, bleeding abnormalities, and lysosomal 
ceroid storage defects such as granulomatous 
colitis, pulmonary fibrosis 
Immunodeficiency in HPS2
CHS LYST OCA with silvery hair, bleeding tendency, peripheral neuropathy, immune deficiency 
GS
          GS1
          GS2
          GS3
MYO5A1
RAB27A
MLPH
OCA with silvery hair
Neurologic impairment in GS1
Hemophagocytic syndrome in GS2
Abbreviations: BLOC1S3, biogenesis of lysosomal organelles complex-1, subunit 3; CHS, Chediak-Higashi syndrome; DTNBP1, dystobrevin-binding protein 
1; GS, Griscelli syndrome; HPS, Hermansky-Pudlak syndrome; LYST, lysosomal trafficking regulator; MATP, membrane-associated transport protein; MLPH, 
melanophilin; MY05A, myosin VA; PLDN, pallidin; OCA, oculocutaneous albinism; RAB27A, Ras-related protein 27A; TYR, tyrosinase; TYRP1 tyrosinase-related 
protein 1.
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are formed through fusion, cytoplasmic injury, and phagocy-
tosis (Nargund et al., 2010). CHS is distinguished by neutro-
phils defective in chemotaxis, mobilization, and bactericidal 
activity, and functionally defective cytotoxic T and natural 
killer cells. This results in recurrent pyogenic infections and 
uncontrolled T-cell and macrophage activation associated 
with a typically fatal hemophagocytic lymphoproliferative 
syndrome, considered the accelerated phase of CHS. 
Most patients with CHS have a functionally null mutant 
CHS1 allele and manifest severe disease in childhood. At 
birth, patients may manifest OCA, exhibiting silvery hair and 
skin hypopigmentation, with cutaneous slate-gray patches 
and tanning capacity after sun exposure. Affected children 
may then develop recurrent infections of the skin, lung, and 
respiratory tract. The accelerated phase may occur soon 
after birth and is characterized by generalized lymphohis-
tiocytic infiltrates, fever, jaundice, hepatosplenomegaly, 
lymphadenopathy, pancytopenia, and bleeding (Nargund 
et al., 2010). Ten to 15 percent of patients manifest ado-
lescent and adult forms associated with missense-mutant 
alleles that encode proteins with partial function (Karim 
et al., 2002). These patients may survive to adulthood but 
develop progressive, often fatal neurologic dysfunction with 
intellectual decline, tremor, ataxia, peripheral neuropathy, 
and white-matter deterioration (Scheinfeld, 2003).
Although treatment of CHS is controversial, further inves-
tigation is critical in an individual with OCA and recurrent 
infections. Blood-smear examination leads to diagnosis 
and implementation of the only curative treatment, bone-
marrow transplant, as fatality is within 30 months of the 
accelerated phase without treatment (Nargund et al., 2010). 
Other modes of therapy are controversial and include par-
enteral vitamin C administration during the stable phase 
in order to normalize neutrophils’ bactericidal activity and 
high-dose methylprednisolone with or without splenectomy 
(Kanjanapongkul, 2006; Nargund et al., 2010).   
Griscelli Syndrome
GS is another rare AR disorder that manifests as partial OCA 
with characteristically silver hair, large pigment conglom-
erates in hair shafts, and accumulation of mature melano-
somes within melanocytes (Mancini, Chan, & Paller, 1998). 
Defects in MYO5A1 and RAB27A cause GS type 1 (GS1) and 
GS type 2 (GS2), respectively, and both map to 15q21.1. 
GS type 3 (GS3) is attributed to mutations in melanophilin 
(MLPH). RAB27A encodes a small GTPase protein, Rab27a, 
which targets the melanosome membrane and binds to 
melanophilin in melanocytes. Molecular motor myosin-Va, 
which is encoded by MYO5A1, is then recruited and permits 
movement of melanosomes along the actin cytoskeleton. 
Figure 2 | Diagnostic algorithm for albinism. Based on clinical signs and symptoms and subsequent clinical and histologic studies and 
genetic testing, OCA, HPS, CHS, and GS can be diagnosed. Abbreviations: CHS, Chediak-Higashi syndrome; GS, Griscelli syndrome; HPS, 
Hermansky-Pudlak syndrome; OCA, oculocutaneous albinism. 
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The tripartite myosin-Va-melanophilin-Rab27a complex 
enables mature melanosomes to migrate to the dendritic 
tips of melanocytes, permitting delivery of melanin to adja-
cent keratinocytes (Al-Idrissi et al., 2010). 
Patients with GS1 develop primary neurologic impairment 
that manifests as muscle hypotonia and intellectual disabil-
ity, as myosin-Va has a critical role in neuron function (Sanal 
et al., 2002). In GS2, however, Rab27a is necessary in lym-
phocyte lytic granule release and lymphocyte homeostasis. 
Correspondingly, there is an uncontrolled T-lymphocyte and 
macrophage activation syndrome known as hemophago-
cytic syndrome (HS), which is associated with lymphocytic 
infiltration of organs and high mortality unless treated with 
hematopoietic stem cell transplantation (Al-Idrissi et al., 
2010; Scheinfeld, 2003). HS may present in the neona-
tal period and is associated with preterm delivery (Lipton, 
Westra, Haverty, Roberts, & Harris, 2004). In contrast, GS3 
is phenotypically restricted to characteristic hypopigmenta-
tion of the skin and hair. 
Rapid diagnosis of GS can occur via light microscopy exami-
nation of a hair shaft demonstrating abnormal aggregates 
of pigment, permitting implementation of appropriate 
counseling and interventions according to the subtype. GS2 
requires early diagnosis and preemptive treatment in order 
to prevent its severe complications (Wong & Yano, 2012). 
CONCLUSION
There is a limited differential of albinism, including few 
genetic syndromes with life-threatening consequences 
(Table 1). Diagnosis can be determined based on pedi-
gree, review of systems, physical exam of skin, hair, and 
eyes, visual evoked potentials, and if indicated, skin biopsy, 
whole-mount platelet electron microscopy studies, blood 
smear, or hair shaft microscopy (Figure 2). Further, genetic 
testing via methods such as RT-PCR and genomic sequenc-
ing can confirm a diagnosis, as well as allow for prenatal 
testing and carrier detection (Falik-Borenstein et al., 1995; 
Santiago Borrero et al., 2006). With diagnosis, appropriate 
recommendations regarding ophthalmologic screening fre-
quency, necessity for ocular muscle surgery, degree of sun 
exposure, and expectations related to systemic complica-
tions can be delineated. Delayed genetic counseling has 
been associated with poor academic performance in OCA, 
hemorrhage in HPS, and mortality in both CHS and GS 
(Torres-Serrant et al., 2010). With knowledge of the differ-
ential in conjunction with the execution of simple diagnostic 
tests, many of these complications can be predicted and 
consequently ameliorated or prevented.
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